LARSEN-&-TOUBRO-INFOTECH
Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), er en global virksomhed inden for teknologirådgivning og digitale løsninger, har udvidet sin aftale med OKQ8 AB Scandinavia. I løbet af de næste fem år vil denne aftale tranformere applikationer og OKQ8’s infrastruktur landskab med tjenester der omfatter Infrastruktur-as-a-Service (IaaS), Sikkerhedstjenester, Applikationsdrift, Vedligeholdelse og Udvikling, hvilket vil resultere i forbedret stabilitet, tilgængelighed og forudsigelighed af it-driften.
OKQ8, der har hovedkvarter i Stockholm, er en af Skandinaviens største brændstofvirksomheder med en omsætning på over 39 mia. SEK og tæt på 1000 stationer over hele Danmark og Sverige. LTI har været partner med OKQ8 siden 2017, og denne udvidede aftaler er et resultat af, hvad dette partnerskab har skabt gennem årene. Som en strategisk partner vil LTI udnytte sine omfattende evner indenfor analyse, automatisering og KI til at levere disse servicer til OKQ8.
Mikael Pålsson, CIO, OKQ8 , udtaler, “For at kunne betjene vores kunder bedre er det afgørende for OKQ8 at integrere vores økosystem som består af brændstofstationer, dagligvarebutikker, bilvaske, biludlejninger samt økonomi- og forsikringsservicer. Som vores strategiske partner bringer LTI den rette erfaring, teknologiske kompetence og kulturelle tilpasning der sikrer, at dette program bliver en fuldkommen succes.”
Arun Sankaranarayanan, Chief Business Officer, LTI Nordics , udtaler, “Siden begyndelsen I 1999 har OKQ8 konsekvent sat høje standarder for teknologiudnyttelse og ekspertise indenfor kundeservice. Vi er glade for at udvide vores partnerskab med OKQ8 for at designe næste generations arkitektur og opfylde virksomhedens vision for digital transformation. LTI vil udnytte sine evner indenfor eksponentielle teknologier og kundecentrisk tilgang til at hjælpe OKQ8 med at nå sine strategiske mål.”
LTI har en stærk tilstedeværelse I hele Norden og samarbejder med førende virksomheder for at hjælpe dem med at konkurrere effektivt i en verden i forandring.
Om LTI:
LTI (NSE: LTI) er en global virksomhed inden for teknologirådgivning og digitale løsninger, der hjælper over 420 klienter med at få succes i en konvergerende verden. Med operationer I 32 lande går vi den ekstra mil for vores klienter og fremskynder deres digitale transformation med LTIs Mosaic platform, som muliggør deres mobile, sociale, analytiske, IoT og cloud-baserede rejser. Vi blev grundlagt I 1997 som et datterselskab af Larsen & Toubro Limited, og vores unikke arv giver os en uovertruffen ekspertise til at løse de mest komplekse udfordringer for virksomheder på tværs af alle brancher. Hver dag giver vores team, på over 30.000 LTI-medarbejdere, vores kunder mulighed for at forbedre effektiviteten af deres forretnings- og teknologidrift samt levere værdi til deres kunder, medarbejdere og aktionærer. Læs mere på http://www.Lntinfotech.com eller følg os på @LTI_Global
Om OKQ8 AB :
OKQ8 Scandinavia: Den foretrukne mulighed for bæredygtig bevægelse
OKQ8 Scandinavia har operationer I Sverige og Danmark og er en af Skandinaviens største brændstofvirksomheder. Vi er en organisation med omkring 5000 ansatte som er engagerede, kundeorienterede og har fokus på bæredygtighed. Vi arbejder aktivt på at drive udviklingen af mere klima- og miljøvenlige brændstoffer og produkter fremad, på at reducere ulighed og på at bidrage til bæredygtige byer og samfund. Med omkring 1000 servicestationer, vores egen bank og et af markedets stærkeste virksomhedstilbud ønsker vi at være den foretrukne mulighed for bæredygtig forretning – både nu og i fremtiden. Læs mere på www.okq8.se
Forbind til LTI:
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200206005412/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum